Mary Jane Geiger

3.4k total citations · 2 hit papers
31 papers, 2.5k citations indexed

About

Mary Jane Geiger is a scholar working on Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism and Genetics. According to data from OpenAlex, Mary Jane Geiger has authored 31 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Cardiology and Cardiovascular Medicine, 13 papers in Endocrinology, Diabetes and Metabolism and 9 papers in Genetics. Recurrent topics in Mary Jane Geiger's work include Cardiac Arrhythmias and Treatments (8 papers), Estrogen and related hormone effects (8 papers) and Cardiac electrophysiology and arrhythmias (7 papers). Mary Jane Geiger is often cited by papers focused on Cardiac Arrhythmias and Treatments (8 papers), Estrogen and related hormone effects (8 papers) and Cardiac electrophysiology and arrhythmias (7 papers). Mary Jane Geiger collaborates with scholars based in United States, Canada and United Kingdom. Mary Jane Geiger's co-authors include Michelle McNabb, Elizabeth Barrett‐Connor, Marcel Kornitzer, Peter Collins, Deborah Grady, Lori Mosca, Nanette K. Wenger, David A. Cox, Claus Christiansen and Steven R. Cummings and has published in prestigious journals such as New England Journal of Medicine, Circulation and Journal of the American College of Cardiology.

In The Last Decade

Mary Jane Geiger

31 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women

2006 735 citations Elizabeth Barrett‐Connor, Lori Mosca et al. New England Journal of Medicine profile →
ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia

2015 418 citations John J.P. Kastelein, Henry N. Ginsberg et al. European Heart Journal profile →

Peers

Countries citing papers authored by Mary Jane Geiger

Since Specialization

Citations

This map shows the geographic impact of Mary Jane Geiger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mary Jane Geiger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mary Jane Geiger more than expected).

Fields of papers citing papers by Mary Jane Geiger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mary Jane Geiger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mary Jane Geiger. The network helps show where Mary Jane Geiger may publish in the future.

Co-authorship network of co-authors of Mary Jane Geiger

This figure shows the co-authorship network connecting the top 25 collaborators of Mary Jane Geiger. A scholar is included among the top collaborators of Mary Jane Geiger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mary Jane Geiger. Mary Jane Geiger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Restricted mean survival time for the analysis of cardiovascular outcome trials assessing non-inferiority: Case studies from antihyperglycemic drug development 2019 ·American Heart Journal ·(unknown), (unknown), Stefan Hantel, B. Nhi Beasley, Lee‐Jen Wei, Mary Jane Geiger, J. Rick Turner, Markus Abt	4
2	ODYSSEY FH I and FH II: 78 week results with alirocumab treatment in 735 patients with heterozygous familial hypercholesterolaemia breakdown → 2015 ·European Heart Journal ·John J.P. Kastelein, Henry N. Ginsberg, Gisle Langslet, G. Kees Hovingh, R Češka, Robert Dufour, Dirk Blom, Fernando Civeira, Michel Krempf, Christelle Lorenzato, Jian Zhao, Robert Pordy, Marie T. Baccara‐Dinet, Daniel A. Gipe, Mary Jane Geiger, Michel Farnier	418
3	Centralized adjudication of cardiovascular end points in cardiovascular and noncardiovascular pharmacologic trials: A report from the Cardiac Safety Research Consortium 2014 ·American Heart Journal ·Jonathan Seltzer, J. Rick Turner, Mary Jane Geiger, Giuseppe Rosano, Kenneth W. Mahaffey, William B. White, (unknown), Norman Stockbridge, Philip T. Sager	19
4	Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes 2014 ·Therapeutic Innovation & Regulatory Science ·Mary Jane Geiger, Cyrus R. Mehta, J. Rick Turner, (unknown), Stefan Hantel, Boaz Hirshberg, Joerg Koglin, Boaz Mendzelevski, Philip T. Sager, Deborah R. Shapiro, Murray Stewart, Thomas G. Todaro, Brenda Gaydos	14
5	Assessment of drug-induced increases in blood pressure during drug development: Report from the Cardiac Safety Research Consortium 2013 ·American Heart Journal ·Philip T. Sager, (unknown), J. Rick Turner, Gary A. Gintant, Mary Jane Geiger, Peter R. Kowey, George A. Mansoor, Boaz Mendzelevski, Eric L. Michelson, Norman Stockbridge, Michael A. Weber, William B. White	18
6	The evaluation and management of drug effects on cardiac conduction (PR and QRS Intervals) in clinical development 2013 ·American Heart Journal ·Adel Nada, Gary A. Gintant, Robert Kleiman, David E. Gutstein, (unknown), Eric L. Michelson, (unknown), Matthew J. Killeen, Mary Jane Geiger, Mónica L. Fiszman, (unknown), Glenn Carlson, Ignacio Rodríguez, Philip T. Sager	43
7	Electrocardiographic assessment for therapeutic proteins—scientific discussion 2010 ·American Heart Journal ·Ignacio Rodríguez, Andrew R. Erdman, Desmond Padhi, Christine Garnett, Hong Zhao, Shari Targum, Suchitra Balakrishnan, (unknown), (unknown), Mary Jane Geiger, Christopher Newton‐Cheh, (unknown), Michael K. Pugsley, Philip T. Sager, Mitchell W. Krucoff, John K. Finkle	23
8	Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women 2006 ·Obstetrical & Gynecological Survey ·Elizabeth Barrett‐Connor, Lori Mosca, Peter Collins, Mary Jane Geiger, Deborah Grady, Marcel Kornitzer, Michelle McNabb, Nanette K. Wenger	39
9	Effects of Raloxifene on Cardiovascular Events and Breast Cancer in Postmenopausal Women breakdown → 2006 ·New England Journal of Medicine ·Elizabeth Barrett‐Connor, Lori Mosca, Peter Collins, Mary Jane Geiger, Deborah Grady, Marcel Kornitzer, Michelle McNabb, Nanette K. Wenger	735
10	Effect of Raloxifene on Cardiovascular Adverse Events in Postmenopausal Women With Osteoporosis 2006 ·The American Journal of Cardiology ·Kristine E. Ensrud, Andrea Riccardo Genazzani, Mary Jane Geiger, Michelle McNabb, Sherie A. Dowsett, David A. Cox, Elizabeth Barrett‐Connor	40
11	Baseline characteristics of menopausal women with coronary heart disease in cardiovascular outcomes clinical trials of menopausal hormone therapy or raloxifene 2005 ·Contemporary Clinical Trials ·Nanette K. Wenger, Mary Jane Geiger	3
12	Interactions Between Transvenous Nonthoracotomy Cardioverter Defibrillator Systems and Permanent Transvenous Endocardial Pacemakers 1997 ·Pacing and Clinical Electrophysiology ·Mary Jane Geiger, Padraig Gearoid O’Neill, Arjun D. Sharma, (unknown), Leandro Ioschpe Zimerman, Ruth Ann Greenfield, Keith H. Newby, J. Marcus Wharton, (unknown), Andrea Natale	14
13	Right Side Implant of the Unipolar Single Lead Defihrillation System 1997 ·Pacing and Clinical Electrophysiology ·Andrea Natale, Jasbír Sra, Mary Jane Geiger, Keith H. Newby, Masood Akhtar, Antonio Pacifico	9
14	Evaluation of the Safety and Efficacy of Deep Sedation for Electrophysiology Procedures Administered in the Absence of an Anesthetist 1997 ·Pacing and Clinical Electrophysiology ·Mary Jane Geiger, Abdul Wase, Margaret M. Kearney, Mary J. Brandon, (unknown), Keith H. Newby, Andrea Natale	33
15	Safety of Slow Pathway Ablation in Patients with Long PR Interval: Further Evidence of Fast and Slow Pathway Interaction 1997 ·Pacing and Clinical Electrophysiology ·Andrea Natale, Ruth Ann Greenfield, Mary Jane Geiger, Keith H. Newby, (unknown), (unknown), Margaret M. Kearney, Mary J. Brandon, Leandro Ioschpe Zimerman	19
16	Safety of transvenous atrial defibrillation in patients with monomorphic ventricular tachycardia and heart disease 1996 ·Journal of the American College of Cardiology ·Andrea Natale, Margaret M. Kearney, Mary J. Brandon, Mary Jane Geiger, (unknown), Gery Tomassoni, (unknown), Keith H. Newby	1
17	Recurrence of neurocardiogenic syncope without pharmacologic interventions 1996 ·The American Journal of Cardiology ·Andrea Natale, Mary Jane Geiger, (unknown), Keith H. Newby, Anwer Dhala, (unknown), (unknown)	45
18	Diverse usage of human T-cell receptor gene segments in HLA-DR1 allospecific T-cell clones 1996 ·Human Immunology ·Masao Ôta, Mary Jane Geiger, Sandra Rosen‐Bronson, Carolyn Katovich Hurley, David D. Eckels	8
19	Safety of Nurse‐Administered Deep Sedation for Defibrillator Implantation in the Electrophysiology Laboratory 1996 ·Journal of Cardiovascular Electrophysiology ·Andrea Natale, Margaret M. Kearney, (unknown), (unknown), Abdul Wase, Keith H. Newby, Ennio Pisanò, Mary Jane Geiger	29
20	Involvement of class II β-chain amino acid residues 85 and 86 in T-cell allorecognition 1990 ·Human Immunology ·David D. Eckels, Mary Jane Geiger, (unknown), Jack Gorski	26

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact